Innovative Liquid Biopsies Epic Sciences specializes in developing advanced liquid biopsy diagnostics that enable non-invasive cancer detection and monitoring, which presents opportunities to collaborate with hospitals and clinics seeking cutting-edge personalized cancer treatment solutions.

Growing Funding and Partnerships With recent Series G funding of $24 million led by prominent investors like Deerfield Management and Arsenal Capital Partners, Epic Sciences is expanding its market reach and capabilities, creating potential for partners interested in joint ventures or licensing opportunities.

Expanding Product Portfolio The launch of the DefineMBC blood test for metastatic breast cancer indicates Epic’s ongoing innovation and product expansion, offering sales opportunities in diagnostic testing kits and lab services to oncology centers and research institutions.

Strategic Leadership Hiring Recent appointments of a CFO and distinguished board members reflect Epic’s focus on strong leadership and governance, which can be leveraged to establish relationships with enterprise clients or partners looking for reliable diagnostic and analytical solutions.

Market Acceleration Epic’s collaborations with major pharmaceutical companies and cancer research centers, coupled with its goal to enhance clinical trial success rates, suggest opportunities to provide supporting technologies, data analytics, and clinical validation partnerships to grow within the oncology ecosystem.